These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62. Elevated Lipoprotein(a) Levels, LPA Risk Genotypes, and Increased Risk of Heart Failure in the General Population. Kamstrup PR; Nordestgaard BG JACC Heart Fail; 2016 Jan; 4(1):78-87. PubMed ID: 26656145 [TBL] [Abstract][Full Text] [Related]
63. Measuring lipoprotein(a) for cardiovascular disease prevention - in whom and when? Thomas PE; Vedel-Krogh S; Nordestgaard BG Curr Opin Cardiol; 2024 Jan; 39(1):39-48. PubMed ID: 38078600 [TBL] [Abstract][Full Text] [Related]
64. Issues in interpreting lipoprotein (a) value as a risk indicator for early cardiovascular disease. Arisaka O; Kojima M; Numata M Acta Paediatr; 2003 Oct; 92(10):1226-7. PubMed ID: 14632346 [No Abstract] [Full Text] [Related]
65. Has lipoprotein 'little' (a) shrunk? Barnathan ES JAMA; 1993 Nov; 270(18):2224-5. PubMed ID: 8411609 [No Abstract] [Full Text] [Related]
66. [Lipoprotein (a), a cardiovascular risk factor: importance of its determination in current clinical practice]. Couderc R; Maachi M J Mal Vasc; 1998 Jun; 23(3):165-75. PubMed ID: 9669219 [TBL] [Abstract][Full Text] [Related]
67. [Primary prevention of cardiovascular diseases by lowering lipids]. Klose G Internist (Berl); 1997 Jun; 38(6):615-6. PubMed ID: 9265009 [No Abstract] [Full Text] [Related]
68. Prevention of cardiovascular complications in patients with Lp(a)-hyperlipoproteinemia and progressive cardiovascular disease by long-term lipoprotein apheresis according to German national guidelines. Klingel R; Heibges A; Fassbender C; Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):38-43. PubMed ID: 28185214 [TBL] [Abstract][Full Text] [Related]
69. Role of lipoprotein(a) in cardiovascular disease current and future perspectives. Berglund L; Anuurad E J Am Coll Cardiol; 2008 Jul; 52(2):132-4. PubMed ID: 18598892 [No Abstract] [Full Text] [Related]
70. [Lipoprotein(a) as a cardiovascular risk factor]. van Lennep JE; Mulder MT Ned Tijdschr Geneeskd; 2011; 155(42):A3582. PubMed ID: 22027461 [TBL] [Abstract][Full Text] [Related]
71. Is it time for a new paradigm in calcific aortic valve disease? Owens DS; Otto CM JACC Cardiovasc Imaging; 2009 Aug; 2(8):928-30. PubMed ID: 19679279 [No Abstract] [Full Text] [Related]
72. Shared genetic risk for sclerosis of valves and vessels. Dorn GW N Engl J Med; 2013 Feb; 368(6):569-70. PubMed ID: 23388009 [No Abstract] [Full Text] [Related]
73. Lipoprotein apheresis in isolated hyperlipoproteinemia(a): a validated treatment or an illusion of validity? Berthold HK; Descamps OS; Gouni-Berthold I Eur J Clin Invest; 2013 Jan; 43(1):108-12. PubMed ID: 23190253 [No Abstract] [Full Text] [Related]
80. Lipoprotein(a) and family history of cardiovascular disease in children with familial dyslipidemias. Guardamagna O; Abello F; Anfossi G; Pirro M J Pediatr; 2011 Aug; 159(2):314-9. PubMed ID: 21392785 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]